Inventor · disambiguated record
Melissa Damschroder
Also filed as: DAMSCHRODER MELISSA · DAMSCHRODER MELISSA MARIE
25 granted patents·23 pending applications·220 citations·filing 2004–2025
96Inventor score
Top patents by PatentIndex Score
48 records- 0195US8697396B2Modulation of antibody effector function by hinge domain engineeringDALL ACQUA WILLIAM·Filed 2011·Granted Apr 15, 2014·40 cites·10 claims
- 0294US9938356B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2015·Granted Apr 10, 2018·26 cites·9 claims
- 0394US9738723B2Humanized anti-OX40 antibodies and uses thereofMEDIMMUNE LLC·Filed 2015·Granted Aug 22, 2017·20 cites·24 claims
- 0493US8323653B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseDAMSCHRODER MELISSA·Filed 2007·Granted Dec 4, 2012·32 cites·9 claims
- 0592US8883992B2Humanized anti-CD19 antibodiesMEDIMMUNE LLC·Filed 2012·Granted Nov 11, 2014·11 cites·9 claims
- 0691US10287362B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2018·Granted May 14, 2019·10 cites·15 claims
- 0791US8008443B2Modulation of antibody effector function by hinge domain engineeringMEDIMMUNE LLC·Filed 2006·Granted Aug 30, 2011·25 cites·8 claims
- 0890US11203633B2Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas pervMEDIMMUNE LTD·Filed 2020·Granted Dec 21, 2021·2 cites·25 claims
- 0989US11059884B2Antibodies directed against Staphylococcus aureus leukotoxinsMEDIMMUNE LLC·Filed 2019·Granted Jul 13, 2021·4 cites·28 claims
- 1088US11072652B2ILT7 binding molecules and methods of using the sameVIELA BIO INC·Filed 2017·Granted Jul 27, 2021·5 cites·24 claims
- 1187US11578119B2Antibodies directed against Staphylococcus aureus leukotoxinsMEDIMMUNE LLC·Filed 2021·Granted Feb 14, 2023·1 cites·20 claims
- 1287US9527905B2Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of useSELLMAN BRET·Filed 2012·Granted Dec 27, 2016·23 cites·9 claims
- 1387US2024417460A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2024·Application pending·0 cites
- 1486US9896505B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseMEDIMMUNE LLC·Filed 2014·Granted Feb 20, 2018·5 cites·8 claims
- 1585US11673950B2ILT7 binding molecules and methods of using the sameVIELA BIO INC·Filed 2021·Granted Jun 13, 2023·1 cites·22 claims
- 1685US11168133B2Combinations of anti-Staphylococcus aureus antibodiesMEDIMMUNE LLC·Filed 2019·Granted Nov 9, 2021·3 cites·22 claims
- 1784US10160812B2Bispecific HER2 antibodiesMEDIMMUNE LLC·Filed 2015·Granted Dec 25, 2018·4 cites·18 claims
- 1881US10597439B2Combination therapies using anti-pseudomonas PSL and PCRV binding moleculesMEDIMMUNE LLC·Filed 2012·Granted Mar 24, 2020·4 cites·7 claims
- 1981US10556968B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Feb 11, 2020·2 cites·8 claims
- 2079US2023340152A1Binding molecules specific for cd73 and uses thereofMEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 2177US12428473B2Combination therapies using anti-pseudomonas PSL and PCRV binding moleculesMEDIMMUNE LTD·Filed 2021·Granted Sep 30, 2025·0 cites·20 claims
- 2275US2023201346A1Binding molecules specific for il-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2373US10022443B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2015·Granted Jul 17, 2018·1 cites·17 claims
- 2473US2021061906A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2020·Application pending·0 cites
- 2572US11525012B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Dec 13, 2022·0 cites·6 claims
- 2672US2023250167A1Ilt7 binding molecules and methods of using the sameVIELA BIO INC·Filed 2023·Application pending·0 cites
- 2772US2025243262A1Combination therapies using anti-pseudomonas psl and pcrv binding moleculesMEDIMMUNE LTD·Filed 2025·Application pending·0 cites
- 2868US9718870B2OX40L fusion proteins and uses thereofMEDIMMUNE LLC·Filed 2015·Granted Aug 1, 2017·1 cites·36 claims
- 2967US11529415B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2020·Granted Dec 20, 2022·0 cites·14 claims
- 3067US10588969B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·0 cites·14 claims
- 3163US2018273621A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2018·Application pending·0 cites
- 3263US2022089699A1Combinations of anti-staphylococcus aureus antibodiesMEDIMMUNE LLC·Filed 2021·Application pending·0 cites
- 3362US2005042664A1Humanization of antibodiesMEDIMMUNE INC·Filed 2004·Application pending·0 cites
- 3462US2009297514A1Humanization of antibodiesMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 3557US2014171623A1Modulation Of Antibody Effector Function By Hinge Domain EngineeringMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 3656US10150815B2Method of treating cancer with humanized anti-OX40 antibodiesMEDIMMUNE LLC·Filed 2017·Granted Dec 11, 2018·0 cites·8 claims
- 3756US2019169303A1Humanized Anti-OX40 Antibodies and Uses ThereofMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 3855US2005048617A1Humanization of antibodiesMEDIMMUNE INC·Filed 2004·Application pending·0 cites
- 3953US2006228350A1Framework-shuffling of antibodiesMEDIMMUNE INC·Filed 2006·Application pending·0 cites
- 4051US2006019342A1Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesisMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 4151US2011077383A1Hinge domain engineeringMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 4247US2010216975A1Framework-Shuffling Of AntibodiesMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 4347US2009220527A1Affinity optimized epha2 agonistic antibodies and methods of use thereofMEDIMMUNE LLC·Filed 2006·Application pending·0 cites
- 4447US2010145028A1Increasing The Production Of Recombinant Antibodies In Mammalian Cells By Site-Directed MutagenesisMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 4545US2015284450A1Combination therapies using anti-pseudomonas psl and pcrv binding moleculesMEDIMMUNE LLC·Filed 2013·Application pending·0 cites
- 4643US2006121042A1Modulation of antibody specificity by tailoring the affinity to cognate antigensMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 4742US2005181479A1Periplasmic expression of antibodies using a single signal sequenceMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 4836US2017183397A1Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereofMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Melissa Damschroder files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →